Neutral
●
GlobeNewsWire
●
5 months ago
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m.